Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib vs Adalimumab vs Placebo in RA (MTX-IR, China)
CTR20130899Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Jul 2014; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20130899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130899.